OCDX · Ortho Clinical Diagnostics Holdings PLC - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 |
|---|---|
| Revenue | $1.77B |
| Cost of Revenue | $908.20M |
| Gross Profit | $858.00M |
| R&D | $112.90M |
| SG&A | $489.60M |
| Total Operating Expenses | $35.30M |
| D&A | $325.90M |
| Operating Income | $88.30M |
| Interest Expense | $198.20M |
| Income Tax | ($13.40M) |
| Net Income | ($211.90M) |
| EPS - Basic | - |
| EPS - Diluted | - |
Balance Sheet
| Line item | FY 2022 |
|---|---|
| Cash & Equivalents | $72.00M |
| Accounts Receivable | $257.20M |
| Inventory | $305.40M |
| Accounts Payable | $181.00M |
| Current Assets | $1.01B |
| Total Assets | $3.36B |
| Current Liabilities | $578.50M |
| Long-term Debt | $2.28B |
| Total Liabilities | $2.95B |
| Stockholders' Equity | ($654.70M) |
| Retained Earnings | ($1.97B) |
Cash Flow
| Line item | FY 2022 |
|---|---|
| Operating Cash Flow | $46.10M |
| Investing Cash Flow | ($45.40M) |
| Financing Cash Flow | $55.80M |
| CapEx | $44.10M |
| Free Cash Flow | $2.00M |
Ratios
| Metric | FY 2022 |
|---|---|
| Profitability | |
| Gross margin | 48.6% |
| Operating margin | 5.0% |
| EBITDA margin | 23.5% |
| Net margin | -12.0% |
| Free cash flow margin | 0.1% |
| FCF / Net income | -0.01 |
| R&D / Revenue | 6.4% |
| SG&A / Revenue | 27.7% |
| Effective tax rate | - |
| Return on assets | -6.3% |
| Return on equity | 32.4% |
| Return on invested capital | 4.3% |
| Liquidity | |
| Current ratio | 1.75 |
| Quick ratio | 1.22 |
| Cash ratio | 0.12 |
| Leverage | |
| Debt / Equity | -3.48 |
| Debt / Assets | 0.68 |
| Debt / EBITDA | 5.50 |
| Interest coverage | 0.4x |
| Equity multiplier | -5.14 |
| Liabilities / Assets | 0.88 |
| Efficiency | |
| Asset turnover | 0.53 |
| Inventory turnover | 2.97 |
| Days sales outstanding | 53d |
| Days inventory outstanding | 123d |
| Days payable outstanding | 73d |
| Cash conversion cycle | 103d |
| Valuation | |
| P / E | - |
| P / B | - |
| P / S | - |
| EV / EBITDA | - |
| Growth | |
| Revenue growth (YoY) | - |
| Revenue CAGR (3y) | - |
| Revenue CAGR (5y) | - |
| Gross profit growth (YoY) | - |
| Operating income growth (YoY) | - |
| Net income growth (YoY) | - |
| EPS growth (YoY) | - |
| EPS CAGR (3y) | - |
| EPS CAGR (5y) | - |
| FCF growth (YoY) | - |
| FCF CAGR (5y) | - |
| Book value growth (YoY) | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2022-01-02.
Business segments
$2.04B totalReportable Segment$2.04B · 100.0%
Product / service
$2.01B totalClinical Laboratories$1.34B · 66.7%
Transfusion Medicine$664.30M · 33.0%
Manufactured Product Other$6.20M · 0.3%
Geographic
$3.09B totalAmericas$1.23B · 39.8%
US$1.02B · 32.9%
EMEA$276.30M · 9.0%
Greater China$274.40M · 8.9%
Other$263.20M · 8.5%
GB$27.50M · 0.9%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
0.11
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✓Operating cash flow positive
- -ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- -Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing Ortho Clinical Diagnostics Holdings plc against the 5 most active filers in the same SIC group.